» Articles » PMID: 32374570

Prevention and Management of Adverse Effects of Disease Modifying Treatments in Multiple Sclerosis

Overview
Specialty Neurology
Date 2020 May 7
PMID 32374570
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: To summarize the currently known side effects of the approved therapies of multiple sclerosis and to suggest monitoring procedures.

Recent Findings: The progress in the treatment of multiple sclerosis with new very effective therapies is accompanied by a number of side effects. Some of these have already been described in the approval studies, but some only after approval in a real world situation. The reason for this is the short duration of the clinical studies, the very heterogeneous patient profile in the real world setting with a number of comorbidities, pretherapies, and wider age range. The side effects may occur during application of therapies or afterwards during the course of the treatment. The side effects may range from mild infections, mild laboratory abnormalities, secondary autoimmune diseases to life-threatening side effects such as progressive multifocal leukoencephalopathy.

Summary: It has to be pointed out that these side effects are not to be considered as final and neurologists should be vigilant against new unknown side effects. The doctor should be aware of these undesirable effects, should weigh the benefits of the therapies against the risks, but at the same time she/he should keep in mind that multiple sclerosis can be a very disabling disease if not treated properly.

Citing Articles

Vaccination status and self-reported side effects after SARS-CoV-2 vaccination in relation to psychological and clinical variables in patients with multiple sclerosis.

Burian K, Heidler F, Frahm N, Hecker M, Langhorst S, Mashhadiakbar P Sci Rep. 2024; 14(1):12248.

PMID: 38806524 PMC: 11133397. DOI: 10.1038/s41598-024-62541-x.


Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.

Frahm N, Ellenberger D, Stahmann A, Fneish F, Luftenegger D, Salmen H Ther Adv Neurol Disord. 2024; 17:17562864241239740.

PMID: 38560408 PMC: 10981260. DOI: 10.1177/17562864241239740.


Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis.

Hecker M, Frahm N, Zettl U Pharmaceutics. 2024; 16(1).

PMID: 38276481 PMC: 10819178. DOI: 10.3390/pharmaceutics16010003.


Vaccination frequency in people newly diagnosed with multiple sclerosis.

Darvishi S, Donnachie E, Gasperi C, Hapfelmeier A, Hemmer B Mult Scler. 2023; 29(14):1831-1840.

PMID: 37830337 PMC: 10687801. DOI: 10.1177/13524585231199084.


Plant-based production of an orally active cyclotide for the treatment of multiple sclerosis.

Jackson M, Xie J, Nguyen L, Wang X, Yap K, Harvey P Transgenic Res. 2023; 32(1-2):121-133.

PMID: 36930229 PMC: 10102037. DOI: 10.1007/s11248-023-00341-1.